Funded Biomarker Testing
15 items
Reflex testing on newly diagnosed tumours with invasive endometrial carcinoma when needed to establish subtype.
Funded Biomarker Disease Site: Endometrium
Biomarker: P53, PR, ER
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North Bay Regional Health Centre, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Reflex testing on newly diagnosed tumours with upper tract (ureter / renal pelvis) urothelial carcinoma.
Funded Biomarker Disease Site: Bladder/ Urothelial
Biomarker: MLH1, MSH2, MSH6, PMS2
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, North York General Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System
Testing to support diagnosis of nasopharyngeal carcinoma (newly diagnosed or suspected nasopharyngeal carcinoma).
Funded Biomarker Disease Site: Head and Neck
Biomarker: EBER
Testing Method:In Situ Hybridization (ISH)
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System